| Name | vascular endothelial growth factor |
|---|---|
| Synonyms | VEGF; VEGF A; VEGFA; VPF; Vascular endothelial growth factor A; Vascular endothelial growth factor A precursor; Vascular permeability factor; vascular endothelial growth factor… |
| Name | cycloheximide |
|---|---|
| CAS |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 18494554 | Masuda K, Teshima-Kondo S, Mukaijo M, Yamagishi N, Nishikawa Y, Nishida K, Kawai T, Rokutan K: A novel tumor-promoting function residing in the 5' non-coding region of vascular endothelial growth factor mRNA. PLoS Med. 2008 May 20;5(5):e94. The 5'UTR-mediated activity was not affected by a protein synthesis inhibitor, cycloheximide. |
5(0,0,0,5) | Details |
| 18075819 | Sena K, Sumner DR, Virdi AS: Modulation of VEGF expression in rat bone marrow stromal cells by GDF-5. Connect Tissue Res. 2007;48(6):324-31. |
5(0,0,0,5) | Details |
| 20153315 | Chu PW, Beart PM, Jones NM: Preconditioning protects against oxidative injury involving hypoxia-inducible factor-1 and vascular endothelial growth factor in cultured astrocytes. Eur J Pharmacol. 2010 May 10;633(1-3):24-32. Epub 2010 Feb 11. The protective effects of DFO and EDHB preconditioning against H (2) O (2) injury were abolished by co-treatment with cycloheximide, an inhibitor of protein synthesis. |
4(0,0,0,4) | Details |
| 15965081 | Chen SD, Hu CJ, Yang DI, Nassief A, Chen H, Yin K, Xu J, Hsu CY: attenuates -induced cytotoxicity in mouse cerebral endothelial cells with HIF-1 activation and VEGF upregulation. Ann N Y Acad Sci. 2005 May;1042:357-64. is a pro-apoptotic lipid messenger that induces oxidative stress and may mediate apoptosis in cerebral endothelial cells (CECs) induced by TNF-alpha/cycloheximide, lipopolysaccharide, oxidized LDL, IL-1, and amyloid peptide. |
4(0,0,0,4) | Details |
| 15714461 | Shi YH, Wang YX, Bingle L, Gong LH, Heng WJ, Li Y, Fang WG: In vitro study of HIF-1 activation and VEGF release by bFGF in the T47D breast cancer cell line under normoxic conditions: involvement of PI-3K/Akt and MEK1/ERK pathways. J Pathol. 2005 Mar;205(4):530-6. In addition, the translation inhibitor cycloheximide confirmed that bFGF-induced HIF-1alpha protein expression was due to de novo protein synthesis. |
4(0,0,0,4) | Details |
| 17122584 | Li QF, Wang XR, Yang YW, Su DS: Up-regulation of hypoxia inducible factor 1alpha by isoflurane in Hep3B cells. Anesthesiology. 2006 Dec;105(6):1211-9. Cycloheximide, an inhibitor for protein synthesis, completely abrogated the induction of HIF-1alpha protein by isoflurane. BACKGROUND: The volatile anesthetic isoflurane induces hypoxia inducible factor (HIF)-1-responsive genes heme oxygenase 1, inducible synthase, and vascular endothelial growth factor (VEGF) expression. |
4(0,0,0,4) | Details |
| 16506055 | Doronzo G, Russo I, Mattiello L, Riganti C, Anfossi G, Trovati M: Insulin activates hypoxia-inducible factor-1alpha in human and rat vascular smooth muscle cells via phosphatidylinositol-3 kinase and mitogen-activated protein kinase pathways: impairment in insulin resistance owing to defects in insulin signalling. Diabetologia. 2006 May;49(5):1049-63. Epub 2006 Feb 28. AIMS/HYPOTHESIS: We previously demonstrated that insulin stimulates vascular endothelial growth factor (VEGF) synthesis and secretion via phosphatidylinositol-3 kinase (PI3-K) and mitogen-activated protein kinase (MAPK) pathways in vascular smooth muscle cells (VSMC) from humans and from insulin-sensitive lean Zucker fa/+ rats. The insulin-induced increase of HIF-1alpha is blunted by the translation inhibitor cycloheximide, LY294002, PD98059, SP600125 and rapamycin, but not by SB203580. |
3(0,0,0,3) | Details |
| 16899596 | Catrina SB, Botusan IR, Rantanen A, Catrina AI, Pyakurel P, Savu O, Axelson M, Biberfeld P, Poellinger L, Brismar K: Hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha are expressed in kaposi sarcoma and modulated by insulin-like growth factor-I. Clin Cancer Res. 2006 Aug 1;12(15):4506-14. The induction suggests a translation mechanism as documented by cycloheximide chase experiment coupled with constant RNA levels as evaluated by quantitative real-time PCR. Hypoxia-inducible factor (HIF), a transcriptional factor composed of two subunits (alpha and beta), plays a key role in this process, activating proangiogenic factors such as vascular endothelial growth factor (VEGF). |
3(0,0,0,3) | Details |
| 17146432 | Yoo YG, Na TY, Yang WK, Kim HJ, Lee IK, Kong G, Chung JH, Lee MO: 6-Mercaptopurine, an activator of Nur77, enhances transcriptional activity of HIF-1alpha resulting in new vessel formation. Oncogene. 2007 May 31;26(26):3823-34. Epub 2006 Dec 4. Here, we demonstrate that 6-mercaptopurine (6-MP), an activator of the NR4A family members, enhances transcriptional activity of HIF-1. 6-MP enhanced the protein-level of HIF-1alpha as well as vascular endothelial growth factor (VEGF) in a dose- and time-dependent manner. The HIF-1alpha protein level remained up to 60 min in the presence of 6-MP when de novo protein synthesis was blocked by cycloheximide, suggesting that 6-MP induces stabilization of the HIF-1alpha protein. |
2(0,0,0,2) | Details |
| 18655183 | Lee DH, Lee YJ: suppresses hypoxia-induced accumulation of hypoxia-inducible factor-1alpha (HIF-1alpha) through inhibiting protein synthesis. J Cell Biochem. 2008 Oct 1;105(2):546-53. In this study, under hypoxic conditions (1% O (2)), we examined the effect of on the intracellular level of HIF-1alpha and extracellular level of vascular endothelial growth factor (VEGF) in a variety of human cancer cell lines. Treatment with 100 microM cycloheximide, a protein synthesis inhibitor, replicated the effect of by inhibiting HIF-1alpha accumulation during hypoxia. |
2(0,0,0,2) | Details |
| 15649403 | Shimizu K, Watanabe K, Yamashita H, Abe M, Yoshimatsu H, Ohta H, Sonoda H, Sato Y: Gene regulation of a novel angiogenesis inhibitor, vasohibin, in endothelial cells. Biochem Biophys Res Commun. 2005 Feb 18;327(3):700-6. Actinomycin D did not alter the kinetics of vasohibin mRNA induction upon VEGF treatment, whereas cycloheximide completely abolished its induction. TNFalpha, IL1 and IFNgamma decreased VEGF-stimulated vasohibin expression. |
1(0,0,0,1) | Details |
| 18173920 | Masuko K, Murata M, Xiang Y, Nakamura H, Yudoh K, Nishioka K, Beppu M, Kato T: Tryptase enhances release of vascular endothelial growth factor from human osteoarthritic chondrocytes. Clin Exp Rheumatol. 2007 Nov-Dec;25(6):860-5. In addition, actinomycin D and cycloheximide did not exert significant inhibition, indicating a regulation of VEGF release by tryptase. |
3(0,0,0,3) | Details |
| 15897232 | Sakao S, Taraseviciene-Stewart L, Lee JD, Wood K, Cool CD, Voelkel NF: Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells. FASEB J. 2005 Jul;19(9):1178-80. Epub 2005 May 16. We have demonstrated that VEGF receptor blockade in combination with chronic hypoxia causes in rats severe angioproliferative pulmonary hypertension (SAPH) associated with arterial occlusion by proliferating endothelial cells, and we postulate that the established, lumen-occluding lesions are the result of the emergence of apoptosis-resistant proliferating cells. |
3(0,0,0,3) | Details |
| 18549879 | Sukhthankar M, Yamaguchi K, Lee SH, McEntee MF, Eling TE, Hara Y, Baek SJ: A green tea component suppresses posttranslational expression of basic fibroblast growth factor in colorectal cancer. Gastroenterology. 2008 Jun;134(7):1972-80. Epub 2008 Mar 8. also inhibits angiogenesis, possibly through the inhibition of proangiogenic factors including vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), which in turn, inhibits tumor growth and metastasis. |
1(0,0,0,1) | Details |
| 18563715 | Thomas R, Kim MH: HIF-1 alpha: a key survival factor for serum-deprived prostate cancer cells. Prostate. 2008 Sep 15;68(13):1405-15. Secondly, cycloheximide, a protein synthesis inhibitor, prevented HIF-1 alpha protein increase in serum-deprived PCa cells. Moreover, the expression of HIF-1 alpha-target genes, VEGF and IGF-2, was concomitantly increased in serum-deprived PCa cells, while suppression of HIF-1 alpha expression significantly inhibited their induction. |
1(0,0,0,1) | Details |
| 18676622 | Lange J, Yafai Y, Reichenbach A, Wiedemann P, Eichler W: Regulation of pigment epithelium-derived factor production and release by retinal glial (Muller) cells under hypoxia. Invest Ophthalmol Vis Sci. 2008 Nov;49(11):5161-7. Epub 2008 Aug 1. In moderate hypoxia, PEDF is downregulated such that the VEGF-to-PEDF ratio increases (and angiogenesis is facilitated). METHODS: PEDF was determined in surgically excised retinal tissue originating from patients with ischemic diabetic retinopathy and in primary guinea pig Muller cell cultures exposed to the protein synthesis inhibitor cycloheximide (CHX) and to hypoxia. |
1(0,0,0,1) | Details |
| 19301310 | Goodyear SM, Kheyfets SB, Garcia FU, Stearns ME: Role of the VEGFR3/VEGFD receptor axis in TGFbeta1 activation of primary prostate cell lines. Prostate. 2009 Jun 15;69(9):982-90. BACKGROUND: Reports indicate that vascular endothelial growth factor receptor type 3 (VEGFR3) regulates cellular functions such as invasion, proliferation, and chemo-resistance. This event was not inhibited by 10 microM cycloheximide or puromycin, indicating transcription and protein synthesis were not required. |
1(0,0,0,1) | Details |
| 16283438 | Yao Y, Kubota T, Sato K, Takeuchi H, Handa Y, Matsukawa S: Cell-specific but p53-independent regulation of vascular endothelial growth factor expression by interferons in human glioblastoma cells. J Neurooncol. 2006 Feb;76(3):219-25. In contrast, induction of VEGF mRNA by IFNs was blocked by the protein synthesis inhibitor cycloheximide. |
118(1,2,2,8) | Details |
| 17331500 | Bian ZM, Elner SG, Elner VM: Regulation of VEGF mRNA expression and protein secretion by TGF-beta2 in human retinal pigment epithelial cells. Exp Eye Res. 2007 May;84(5):812-22. Epub 2007 Jan 9. Stimulation of VEGF expression by TGF-beta2 was blocked by cycloheximide, suggesting that de novo protein synthesis is required. |
92(1,1,1,12) | Details |
| 16549420 | Na YJ, Yang SH, Baek DW, Lee DH, Kim KH, Choi YM, Oh ST, Hong YS, Kwak JY, Lee KS: Effects of peritoneal fluid from endometriosis patients on the release of vascular endothelial growth factor by neutrophils and monocytes. Hum Reprod. 2006 Jul;21(7):1846-55. Epub 2006 Mar 20. The VEGF mRNA expression levels in the neutrophils were higher in the EPF, which was abrogated by cycloheximide, suggesting that the EPF induces the production of VEGF in neutrophils. |
90(1,1,1,10) | Details |
| 17240354 | Sato F, Imaizumi T, Sashinami H, Yoshida H, Kusumi T, Mori F, Wakabayashi K, Nakane A, Satoh K, Kijima H: Upregulation of vascular endothelial growth factor by heat-killed Listeria monocytogenes in macrophages. Biochem Biophys Res Commun. 2007 Mar 9;354(2):608-12. Epub 2007 Jan 16. Pretreatment of cells with cycloheximide, a protein synthesis inhibitor, inhibited the induction of VEGF mRNA by HKLM. |
88(1,1,1,8) | Details |
| 16514669 | Vogt RR, Unda R, Yeh LC, Vidro EK, Lee JC, Tsin AT: Bone morphogenetic protein-4 enhances vascular endothelial growth factor secretion by human retinal pigment epithelial cells. J Cell Biochem. 2006 Aug 1;98(5):1196-202. Addition of cycloheximide (CHX) or actinomycin-D (ACT) significantly reduced VEGF secretion from cells treated with BMP-4, suggesting that the BMP-4-induced secretion of VEGF requires new RNA and protein synthesis. |
87(1,1,1,7) | Details |
| 16293985 | Sarker KP, Biswas KK, Yamaji K, Yamakuchi M, Hashiguchi T, Lee KY, Maruyama I: Inhibition of thrombin-induced vascular endothelial growth factor production in human neuroblastoma (NB-1) cells by argatroban. Pathophysiol Haemost Thromb. 2005;34(1):41-7. In these cells, we further show that thrombin-induced VEGF secretion was blocked by cycloheximide and actinomycin D, indicating that de novo protein synthesis is essential for this process. |
87(1,1,1,7) | Details |
| 17257889 | Nakagawa H, Matsumiya T, Sakaki H, Imaizumi T, Kubota K, Kusumi A, Kobayashi W, Kimura H: Expression of vascular endothelial growth factor by photodynamic therapy with mono-L-aspartyl chlorin e6 (NPe6) in oral squamous cell carcinoma. Oral Oncol. 2007 Jul;43(6):544-50. Epub 2007 Jan 25. The expression mRNAs for VEGF, c-jun and c-fos induced by Npe6-mediated PDT were inhibited by SB203580, p38 MAPK inhibitors, and the expression of VEGF mRNA was inhibited by cycloheximide (CHX), a protein synthesis inhibitor. |
86(1,1,1,6) | Details |
| 16808811 | Beckert S, Farrahi F, Aslam RS, Scheuenstuhl H, Konigsrainer A, Hussain MZ, Hunt TK: Lactate stimulates endothelial cell migration. Wound Repair Regen. 2006 May-Jun;14(3):321-4. This effect was blocked by anti-VEGF and by cycloheximide. |
36(0,1,1,6) | Details |
| 17678892 | Clere N, Bermont L, Fauconnet S, Lascombe I, Saunier M, Vettoretti L, Plissonnier ML, Mougin C: The human papillomavirus type 18 E6 oncoprotein induces Vascular Endothelial Growth Factor 121 (VEGF121) transcription from the promoter through a p53-independent mechanism. Exp Cell Res. 2007 Sep 10;313(15):3239-50. Epub 2007 Jul 17. Treatment with cycloheximide did not inhibit E6-induced VEGF121 expression. |
5(0,0,0,5) | Details |